Chapter XIII of Annex II to the EEA Agreement shall be amended as follows:
The text of point 15p (Directive 2001/82/EC of the European Parliament and of the Council) shall be deleted with effect from 28 January 2022.
The following indent is added in points 15q (Directive 2001/83/EC of the European Parliament and of the Council) and 15zr (Regulation (EC) No 1901/2006 of the European Parliament and of the Council):
‘— 32019 R 0005: Regulation (EU) 2019/5 of the European Parliament and of the Council (OJ L 4, 7.1.2019, p. 24).’
Point 15zb (Regulation (EC) No 726/2004) shall be amended as follows:
the following indent is added:
‘— 32019 R 0005: Regulation (EU) 2019/5 of the European Parliament and of the Council (OJ L 4, 7.1.2019, p. 24).’
the text of the adaptation is replaced by the following:
‘The powers vested in the European Commission in relation to the infringement procedure foreseen in Article 84a, including the power to impose financial penalties on the holders of marketing authorisations, shall, in the cases where the marketing authorisation holder is established in an EFTA State, be carried out by the EFTA Surveillance Authority in close cooperation with the Commission. Before the EFTA Surveillance Authority takes a decision regarding financial penalties, the Commission shall provide it with its assessment and a proposal on how to act.’
The following is inserted after point 21 (Commission Implementing Regulation (EU) 2017/556):
‘22. 32019 R 0006: Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on veterinary medicinal products and repealing Directive 2001/82/EC (OJ L 4, 7.1.2019, p. 43).
The provisions of this Regulations shall, for the purposes of the EEA Agreement, be read with the following adaptations:
The following provisions of the Regulation regarding veterinary matters shall not apply to Liechtenstein:
Article 57
Articles 103 to 115, included.
Liechtenstein shall not be obliged to participate in the decentralised procedure (DCP) and in the mutual recognition procedure (MRP) and shall, therefore, not be obliged to issue the corresponding marketing authorisations. Instead, Austrian marketing authorisations within the DCP and the MRP shall be valid for Liechtenstein upon request of a marketing authorisation applicant.
In Article 136, the powers vested in the European Commission to impose financial penalties on the holders of marketing authorisations shall, in the cases where the marketing authorisation holder is established in an EFTA State, be carried out by the EFTA Surveillance Authority in close cooperation with the Commission. Before the EFTA Surveillance Authority takes a decision regarding financial penalties, the Commission shall provide it with its assessment and a proposal on how to act.’